Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry-Reference-Cited by-同舟云学术

Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry

Published:2020-08-11 Issue:5 Volume:105 Page:561-570
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur. J. Haematol.

Author:

Röth Alexander¹,Araten David J.²,Larratt Loree³,Kulasekararaj Austin G.⁴,Maciejewski Jaroslaw P.⁵,Wilson Amanda⁶,Gustovic Philippe⁷,Kanakura Yuzuru⁸

Affiliation:

1. West German Cancer Center University Hospital Essen University of Duisburg‐Essen Essen Germany

2. NYU Langone Medical Center New York NY USA

3. University of Alberta Edmonton AB Canada

4. King’s College Hospital NIHR/Wellcome King’s Clinical Research Facility London UK

5. Taussig Cancer Institute Cleveland Clinic Cleveland OH USA

6. Alexion Pharmaceuticals, Inc. Boston MA USA

7. Alexion Pharma GmbH Zürich Switzerland

8. Osaka University Graduate School of Medicine Suita Osaka Japan

Funder

Alexion Pharmaceuticals

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13485

Reference32 articles.

1. Paroxysmal nocturnal hemoglobinuria

2. Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry

3. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry

4. Advances in understanding the pathogenesis of acquired aplastic anaemia

5. Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Attack of the Clones: A Patient With Untreated Aplastic Anemia Presenting With Classical Paroxysmal Nocturnal Hemoglobinuria;Cureus;2023-01-23

2. Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands;The European Journal of Health Economics;2023-01-12

3. Not So Benign Cold Agglutinin Disease: New Direction for an Old Disease;The Hematologist;2023

4. Monoclonal antibodies used for the management of hemataological disorders;Expert Review of Hematology;2022-05-04

5. Monoclonal antibodies used for management of hematological disorders;Journal of Hematology and Allied Sciences;2021-05-31